Motif Bio plc announced that Stephanie Noviello, MD, MPH has joined the company as Vice President, Clinical Development. She will report to David Huang, MD, PhD, Chief Medical Officer. Dr. Noviello will be a key contributor to the European Marketing Authorisation Application submission for iclaprim. Dr. Noviello joins Motif Bio from Bristol-Myers Squibb, where she most recently was Clinical Program Lead, Virology. In this position, she served as clinical lead for the hepatitis B and C and HIV portfolios. She previously worked at Schering-Plough Research Institute as a Director in Hepatology. Prior to working in industry, she was an Epidemic Intelligence Service Officer at the US Centers for Disease Control and Prevention stationed with the New York State Department of Health Bureau of Communicable Disease Control.